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Increasing evidence indicates that insulin-like growth factor-I
(IGF-I) has an important role in oligodendrocyte development.
In this study, we examined myelination during postnatal devel-
opment in IGF-I knock-out (KO) mice by assessing myelin
staining, the expression of myelin basic protein (MBP) and
proteolipid protein (PLP), two major myelin-specific proteins, and
the number of oligodendrocytes and their precursors. For com-
parison, we also measured the expression of median subunit of
the neuron-specific intermediate filament, M-neurofilament (M-
NF), to obtain an index of the effects of IGF-I deficiency on
neurons. We found that myelin staining, MBP and PLP expres-
sion, and the percentage of oligodendrocytes and their precur-
sors are significantly reduced in all brain regions of developing
IGF-I KO mice but are similar to controls in adult IGF-I KO mice.
In contrast, the abundance of M-NF was decreased in both the
developing and adult brain of IGF-I KO mice. We also found that
IGF-II protein abundance is increased in the brains of IGF-I KO
mice. Our data indicate, therefore, that myelination during early
development is altered in the absence of IGF-I by mechanisms
that involve a reduction in oligodendrocyte proliferation and
development. Although neuronal actions cannot be excluded in
the myelin normalization, the reduced axonal growth suggested
by the reduced M-NF expression makes a role for neuronal
factors less compelling. These data suggest that IGF-I plays a
significant role in myelination during normal early development
and that IGF-II can compensate in part for IGF-I actions on
myelination.
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In the CNS, myelination is characterized by proliferation and
differentiation of oligodendrocyte precursors and accumulation of
myelin-associated proteins and lipids. In rodents, myelination
begins in the first postnatal week and peaks at 3–4 weeks
(Morell, 1984; Jacobson, 1991). Increasing evidence indicates that
insulin-like growth factor-I (IGF-I) has an important role in
myelination. In culture, IGF-I increases the number of oligoden-
drocytes and their precursors by mechanisms involving promo-
tion of oligodendrocyte precursor proliferation, differentiation,
and survival (McMorris et al., 1986; McMorris and Dubois-
Dalcq, 1988; Saneto et al., 1988; Mozell and McMorris, 1991;
Barres et al., 1992; Ye and D’Ercole, 1999). Consistent with in
vitro data, we (Ye et al., 1995a,b; Mason et al., 2000) and others
(Carson et al., 1993) have demonstrated that brain IGF-I over-
expression in transgenic (Tg) mice increases myelination by in-
creasing oligodendrocyte number, myelin protein gene expres-
sion, and myelin sheath thickness. Conversely, inhibition of IGF-I
bioactivity by ectopic expression of IGF binding protein-1
(IGFBP-1) in brain decreases myelination (Ye et al., 1995a,b).
Like IGFBP-1 Tg mice, mice with ablated IGF-I gene expres-
sion [IGF-I knock-out (KO) mice] exhibit a decreased number of
oligodendrocytes and myelinated axons in corpus callosum (CC)
and anterior commissure (Beck et al., 1995). More recently,
Cheng et al. (1998) reported that myelin-associated galactocere-
broside and sulfatide are reduced by 25% in the brains of adult
IGF-I KO mice but that the concentration of myelin and myelin-
specific proteins does not differ from those in wild-type (WT)
controls. Based on these findings, Cheng et al. concluded that
IGF-I does not have a major role in myelination during develop-
ment and that axonal factors other than IGF-I determine oligo-
dendrocyte survival and myelination. These investigators, how-
ever, only examined myelination in adult IGF-I KO mice, leaving
open the possibility that myelination is altered during develop-
ment in the absence of IGF-I expression. In addition to IGF-I,
IGF-II and insulin (in high concentrations) can transduce signals
through interaction with the type 1 IGF receptor. It seems pos-
sible, therefore, that IGF-II (and possibly other agents) can serve
as surrogates when IGF-I is deficient and mask the normal role of
IGF-I in myelination in IGF-I KO mice.
To investigate these possibilities, we examined myelination and
IGF-II expression during early postnatal development. We also
measured the expression of the neuron-specific intermediate fil-
ament neurofilament (NF) to obtain an index of the effects of
IGF-I deficiency on neurons. Here we provide evidence that
myelination is significantly reduced in developing IGF-I KO
mice. We also show that IGF-II protein abundance is increased in
the brains of IGF-I KO mice, suggesting that the increased IGF-II
expression may compensate for the loss of IGF-I and its func-
tions. Although we cannot exclude a role for neurons in the
myelin normalization, the reduced axon growth suggested by the
reduced median subunit of the neuron-specific intermediate neu-
rofilament (M-NF) expression makes this less compelling. These
data suggest, therefore, that IGF-I plays a significant role in
myelination during normal early development.
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MATERIALS AND METHODS
Mice. IGF-I KO mice (Liu et al., 1993) were a generous gift from Dr.
Argiris Efstratiadis (Columbia University, New York, NY) and were
housed at National Institute of Environmental Health Sciences (Re-
search Triangle Park, NC). Homozygous IGF-I KO mice were obtained
by breeding heterozygous males with heterozygous females, and only
male IGF-I KO mice were studied. Consistent with a previous report
(Liu et al., 1993), 20% of homozygous IGF-I KO mice survived
postnatally. Homozygous, heterozygous, and WT mice were routinely
identified by PCR of tail genomic DNA, using specific oligonucleotide
primers, as reported previously (Richards et al., 2001). Mice were main-
tained with 12 hr light /dark cycles at 22°C. All procedures used were
consistent with the guidelines of National Institutes of Health and
approved by institutional review committees of the University of North
Carolina at Chapel Hill and the National Institute of Environmental
Health Sciences.
Northern blot hybridization analysis. Total RNA was extracted using the
acidic guanidinium thiocyanate–phenol–chloroform method (Chom-
czynski and Sacchi, 1987). Aliquots of 15–20 g of total RNA were
electrophoresed, transferred onto nylon membranes, and UV cross-
linked. After staining with 0.02% methylene blue, membranes were
photographed to quantify the amount of RNA transferred and then
hybridized with 32P-labeled single-stranded DNA (ssDNA) probes in
Church’s buffer (0.5 M sodium phosphate, pH 7.1, 7% SDS, and 0.1 mM
EDTA) and washed at high stringency with 40 mM sodium phosphate and
1% SDS at 55°C for 60 min. After autoradiography, membranes were
stripped and hybridized with a second probe.
Quantification was performed using a computer-assisted image analy-
sis system (Image-Pro; Media Cybermetics, Silver Spring, MD). To
ensure the accuracy of changes in mRNA abundance and equal loading
of RNA, the mRNA levels were normalized to cyclophilin (CYC)
mRNA abundance or to the amount of 18 S rRNA on the membrane
visualized by methylene blue staining. The abundance of CYC mRNA
closely paralleled the amount of 18 S rRNA transferred.
Probes. Proteolipid protein (PLP), myelin basic protein (MBP), and
CYC DNA fragments were amplified by PCR and used as templates for
probes, as described in our previous report (Ye et al., 1995a). The PLP
DNA fragment corresponded to base pairs (bp) 268–903 of mouse PLP
cDNA (Hudson et al., 1987), the MBP DNA fragment corresponded to
bp 58–490 of the mouse MBP cDNA (Newman et al., 1987), and the
CYC DNA fragment corresponded to bp 106–517 of the rat CYC cDNA
(Danielson et al., 1988). ssDNA hybridization probes were generated
from these templates by linear PCR (Ye et al., 1992, 1995a) using their
respective 3 end primers and 32P-labeled dCTP (Amersham Bio-
sciences, Arlington Heights, IL).
Western blot analysis. Protein from each brain region was extracted as
described previously (Klugmann et al., 1997). Briefly, pulverized tissues
were lysed in 1% SDS and 1 PBS and sonicated, and the resultant
homogenates were boiled for 3–5 min. Supernatants were collected by
centrifugation at 12,000 rpm for 5 min at 4°C and stored at 80°C until
use. Protein concentration was determined with the BCA protein kit
(Pierce, Rockford, IL) using bovine serum albumin as a standard. Ali-
quots of 15–30 g of protein (80 g of protein for IGF-II) were separated
on 7.5 or 12.5% polyacrylamide gel and transferred onto polyvinylidene
difluoride membrane (Amersham Biosciences). Specific proteins were
detected using their specific antibody and visualized using ECL kits
(Amersham Biosciences) or ABC colometric kit (Vector Laboratories,
Burlingame, CA). Primary antibodies were used and obtained as follows:
anti-MBP antibody (1:1500), anti-M-NF antibody (1:1000), anti-H-NF
antibody (1:1000), and anti-glial fibrillary acidic protein (GFAP) (1:3000)
were obtained from Chemicon (Temecula, CA); anti-PLP antibody (1:
500) was obtained from Biogenesis (Brentwood, NH); and anti-IGF-II
antibody (1:200), anti-IGF-IR  subunit (1:1000), anti-insulin receptor
substrate 1 (IRS1) antibody (1:1000), anti-IRS2 (1:1000), and anti-IRS4
antibody (1:1000) were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Human recombinant IGF-II (Eli Lilly, Indianapolis, IN) was
a gift from Dr. Marsh Davenport (University of North Carolina at
Chapel Hill) or obtained from Santa Cruz Biotechnology. Quantification
of specific protein abundance was performed using a computer-assisted
image analysis system (Image-Pro; Media Cybermetics). To ensure the
equal loading and accuracy of changes in protein abundance, the protein
levels were normalized to actin abundance. The abundance of actin
closely paralleled the amount of total protein loaded.
Histochemical and immunohistochemical staining. Brains were perfused
by transcardial infusion of 4% paraformaldehyde in PBS and further
fixed in the same fixative overnight. Brains were split along the middle
sagittal line. Left hemispheres were paraffin embedded and sagittally
sectioned at a thickness of 6 m for myelin staining using the Luxol Fast
Blue–Periodic Acid Schiff (LFB-PAS) method and glutathione
S-transferase (GST)- (1:500) immunostaining. Right hemispheres were
cryoprotected with 20% sucrose and sagittally frozen sectioned at a
thickness of 10 m. Sections were washed with 1 PBS and incubated
with a polyclonal antibody specific for IGF-II (1:200; Santa Cruz Bio-
technology), NG2 (1:200; a gift from Dr. Bill Stallcup, The Burnham
Institute, La Jolla, CA), PLP (1:500), or MBP (1:250; Chemicon). An-
tibody–antigen complexes were detected using either a rhodamine-
conjugated anti-rabbit IgG antibody or an ABC kit and peroxidase
(Vector Laboratories) and visualized by incubation with DAB.
Quantification of oligodendrocytes. To quantify the number of oligo-
dendrocytes and their precursors, sections were immunostained with
GST- antibody or NG2 antibody, respectively, and a peroxidase-
conjugated secondary antibody. They then were counterstained with
hematoxylin. Images of labeled cells (blue hematoxylin-stained nuclei
and yellowish brown-immunostained cells) were digitally captured using
a microscope and a Spot Jr. digital camera (Diagnostic Instruments,
Sterling Heights, MI). Only immunolabeled cells with clear nuclei were
scored. The number of GST--positive cells or NG2-positive oligoden-
drocyte precursors was calculated as percentage of total number of cells
as judged by the number of nuclei. In each section, 300–500 cells in CC
and brainstem (BS) and 400–600 cells in cerebral cortex (CTX) were
counted. Overestimates of cell number attributable to splitting of nuclei
were corrected using Abercrombie’s methods (Abercrombie, 1946).
Statistics. Student’s t test was used with assistance of SigmaStat soft-
ware for Widows (SPSS, Chicago, IL).
RESULTS
Compared with those of WT littermate controls (Fig. 1), brains of
IGF-I KO mice were significantly reduced in weight from the
earliest time measured (1 week of age). These results are consis-
tent with data reported previously (Beck et al., 1995; Cheng et al.,
1998). To determine whether there are regional alterations in
brain growth during development, brains from developing IGF-I
KO mice, as well as WT controls, were dissected into five distinct
regions [CTX, hippocampus (HIP), diencephalon (DIE), cere-
bellum (CB), and BS] and weighed. Compared with WT controls,
the weights of all five regions were significantly decreased in
IGF-I KO mice at all ages examined (Fig. 1). There was no
significant difference in brain weight between WT and heterozy-
gous IGF-I KO mice, and, therefore, the data from WT and
heterozygous IGF-I KO mice were grouped for additional anal-
yses and referred to as littermate control or as control mice.
We first tested whether blunting of IGF-I expression during
early development affects myelination using LFB-PAS staining as
an index. As Figures 2 and 3 show, myelin is stained light blue, cell
nuclei is stained dark blue, and hydrocarbonates are stained
pink/purple. In control mice, the abundance of light blue-stained
myelin gradually increased during the developmental period stud-
ied. At 1 week of age, myelin was readily observed in BS and CB.
Light blue-stained myelin became evident in CTX of 2-week-old
mice, and bundles of myelinated fibers were observed in CC, BS,
DIE, olfactory bulb, and other brain regions at this time. Myelin
staining significantly increased during the next several weeks in
all brain regions. Representative microphotographs of LFB-PAS
staining in developing CTX and BS are shown in Figures 2 and 3,
respectively. Myelin staining in IGF-I KO mice followed a similar
developmental pattern. Compared with control mice, however,
myelin staining in IGF-I KO mice was significantly reduced in the
first 3 weeks of life. Myelin staining in most brain regions of IGF-I
KO mice gradually increased and became similar to that in
control mice at 10 weeks of age (Figs. 2, 3). It appears, however,
that the myelin content in CC of IGF-I KO mice remained less
than that of littermate controls (Fig. 2). Immunostaining of MBP
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and PLP, two major myelin-specific proteins, exhibited similar
patterns of change during development (data not shown).
To quantify changes in myelination during development, we
examined the expression of MBP and PLP, using Western immu-
noblot and Northern blot hybridization analysis. At 2 weeks of
age, four major MBP bands (14.4, 17, 18, and 21 kDa) and
a single PLP band (30 kDa) are readily detected by Western
immunoblot analysis (Fig. 4). The abundance of both MBP and
PLP proteins in IGF-I KO mice was significantly decreased in all
five regions examined compared with littermate controls. When
the abundance of all four MBP bands is combined for quantifi-
cation, MBP protein in IGF-I KO mice was decreased by 80%
in CTX, 85% in HIP, 75% in DIE, 60% in BS, and 65%
in CB. PLP protein abundance was also significantly reduced in
IGF-I KO mice, being 30% of littermate controls in CTX,
45% in HIP, 60% in DIE, 50% in BS, and 55% in CB.
As reported previously (Ye et al., 1995a), although a single
band of MBP mRNA at size of 3 kb was detected, doublet
bands of PLP mRNA at 2.4 and 3.2 kb were clearly observed
(Fig. 5), and a third PLP mRNA at 1.6 kb was detected only
after prolonged exposure. Consistent with the changes in protein
abundance, mRNA for MBP and PLP in 2-week-old IGF-I KO
mice also was decreased (Fig. 5). In IGF-I KO mice, the abun-
dance of MBP mRNA was 10, 50, and 30% of control mice
in CTX, BS, and DIE, respectively. Similarly, when compared
with those in control mice, PLP mRNA abundance (quantified by
combining both the 2.4 and 3.2 kb mRNAs) in the CTX, BS,
and DIE of IGF-I KO mice was decreased by 60, 50, and
60%, respectively. A single experiment also showed that MBP
and PLP mRNA abundance in HIP and CB was significantly
decreased in IGF-I KO mice (data not shown).
Next we determined whether the reduced expression of MBP
and PLP observed in 2-week-old IGF-I KO mice persisted at later
development stages. In this experiment, we focused on CTX and
BS, because these regions undergo myelination at different times,
with myelination occurring earlier in BS than CTX. As Figure 6A
shows, the abundance of MBP and PLP protein in both CTX and
BS of control mice rapidly increases during the first 3 weeks of life
and increased only modestly thereafter. Also as expected, accumu-
lation of these proteins begins later in CTX than in BS. The
expression of MBP and PLP proteins in the CTX and BS of IGF-I
KO mice followed a similar developmental pattern. When com-
pared with control mice, the abundance of MBP and PLP proteins
in both CTX and BS of IGF-I KO mice was significantly reduced
during their first 3 weeks of postnatal life (Fig. 6B). With increas-
ing age, however, the MBP and PLP protein abundance in IGF-I
KO mice gradually increased and became similar to that in controls
by 10 weeks of age. The abundance of MBP mRNA in CTX,
DIE, and BS exhibited a similar pattern of changes (Fig. 6C).
To determine whether the alterations in the MBP and PLP
expression in the IGF-I KO mice were attributable to changes in
the development of oligodendrocytes, we quantified the number
of oligodendrocytes and their precursors during development.
Mature oligodendrocytes and their precursors in the frontal CTX
(layers 2–6), CC and BS were identified using antibody against
the cell body markers GST- and NG2, respectively. Because
blunting IGF-I expression significantly increases cell density (Liu
et al., 1993; Beck et al., 1995; Cheng et al., 1998), we measured
oligodendrocytes and precursors as percentage of total cells.
In 1-week-old control mice, NG2-positive oligodendrocyte pre-
cursors were relatively abundant, being 9.9% of total cells in
CTX, as judged by nuclear staining, 49% in CC, and 17% in
BS. With age, the number of NG2-positive oligodendrocyte pre-
cursors gradually decreased in all brain regions. Compared with
control mice, the number of NG2-positive cells was significantly
reduced in 3-week-old and 10-week-old IGF-I KO mice (Fig. 7).
In 3-week-old IGF-I KO mice, the percentage of NG2-positive
cells in CTX, CC, and BS was 63, 78, and 68% of controls,
respectively, and was 64, 76, and 80% of controls at 10
weeks of age. One-week-old IGF-I KO mice also exhibited 10–
12% decreases in the three brain regions examined, but the
reduction was not statistically significant (Fig. 7), possibly attrib-
utable to large variation among samples.
As reported previously (Tansey and Cammer, 1991; Cammer
and Zhang, 1992; Mason et al., 2000), GST--positive cells ex-
hibit a small cell body with a few of the processes. In contrast to
NG2-positive precursors, GST--positive oligodendrocytes were
rarely observed in 1-week-old control mice (data not shown), and
their number gradually increased with age in all brain regions. In
3-week-old control mice, the percentage of GST--positive oligo-
dendrocytes was 6, 40, and 20% of total cell number in
CTX, CC, and BS, respectively. The oligodendrocyte number
reaches 12% of the total cell number in CTX, 55% in CC, and
26% in BS at 10 weeks. These values are similar to those
determined using PLP in situ hybridization (Ye et al., 1995a).
Figure 1. Weights of whole brain and brain regions in IGF-I KO and
control mice during development. Brains were collected from IGF-I KO
mice (open circles) and their littermate controls ( filled circles), dissected,
and weighed. Values are means  SE from 6–10 mice. Absence of error
bars indicates that the variance is smaller than the area encompassed by
the symbol. WB, Whole brain. At each age studied, the weights recorded
for IGF-I KO and control mice were significantly different ( p  0.01).
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Figure 2. Myelin staining of CTX from IGF-I KO and littermate control mice during development. Brains of IGF-I KO mice (E–H) and their littermate
controls (A–D) were perfusion fixed with 4% paraformaldehyde, sectioned, and stained using the LFB-PAS method. Myelin is stained light blue, nuclei
are dark blue, and hydrocarbonates are pink/purple. Sections from mice at 1 week of age are shown in A and E, 2 weeks are shown in B and F, 3 weeks
are shown in C and G, and 10 weeks are shown in D and H. Scale bar, 50 m.
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Figure 3. Myelin staining of brainstem from IGF-I KO and littermate control mice during development. Brains of IGF-I KO mice (E–H) and their
littermate controls (A–D) were perfusion fixed with 4% paraformaldehyde, sectioned, and stained using the LFB-PAS method. Sections from mice at
1 week of age are shown in A and E, 2 weeks are shown in B and F, 3 weeks are shown in C and G, and 10 weeks are shown in D and H. Scale bar, 50 m.
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Consistent with Western immunoblot analysis, the number of
GST--positive cells in 3-week-old IGF-I KO mice is reduced in
all three regions examined, being 60, 67, and 71% of control
CTX, CC, and BS, respectively (Fig. 7). At 10 weeks, the number
of GST--positive oligodendrocytes was moderately decreased in
the three regions of IGF-I KO mice. The decreases, however,
were not statistically significant (Fig. 7).
To examine the relationship between myelination and axon
development in IGF-I KO mice, we determined the abundance of
NF protein in developing and adult IGF-I KO mice and their
littermate controls. NF is a neuron-specific intermediate filament
and plays an important role in determining axon caliber. As
Figure 8 shows, M-NF protein, a medium subunit of NF, was
abundant in the CTX and BS of 1-week-old controls. Its abun-
dance gradually increased during development, as reported pre-
viously (Julien et al., 1986; Hoffman et al., 1987). Compared with
control mice, the abundance of CTX and BS M-NF protein was
significantly reduced in the developing IGF-I KO mice, being
60–80% of control mice (Fig. 8B). Unlike the changes in myelin-
specific proteins, the changes in abundance of M-NF did not
recover and remained reduced by 40% in 10-week-old IGF-I
KO mice (Fig. 8C). The abundance of another neurofilament
subunit, H-NF, in CTX of IGF-I KO mice exhibited a similar
pattern of change and was significantly reduced when compared
with control mice (data not shown).
The abundance of GFAP, an astrocyte-specific filament pro-
tein, was also quantified. Similar to NF abundance, the abun-
dance of GFAP gradually increased during development (Fig.
8A). Its abundance in IGF-I KO mice, however, did not signifi-
cantly differ from that in control mice (Fig. 8A).
We next investigated possible mechanism(s) for the “catch-up”
in myelination that we observed in IGF-I KO mice. Because
IGF-II is capable of interacting with the IGFIR (Kiess et al.,
1987; Gustafson and Rutter, 1990) and promoting oligodendro-
cyte development in culture (McMorris et al., 1990; Masters et
al., 1991; Barres et al., 1992), we asked whether there is an
increase in IGF-II expression that might compensate for the
IGF-I deficit. We also examined the abundance of IGFIR and
IRS-1, IRS-2, and IRS-4, the three IRSs expressed in brain, to
determine whether there is any alteration in their expression.
Western immunoblots of protein extracts from the CTX using
IGF-II antibody identified a band migrating at an apparent mass
of 7.5 kDa and a more abundant doublet band of 12 kDa.
Figure 4. MBP and PLP protein abundance in 2-week-old IGF-I KO and
littermate control mice. A, Representative Western immunoblot of MBP
and PLP protein in brain regions of 2-week-old IGF-I KO and littermate
control mice. The IGF-I KO mouse is indicated by KO. After detection
with anti-MBP antibody, the blot was stripped and reprobed with anti-
bodies to PLP and actin. B, Quantitative analysis of MBP and PLP
protein abundance in 2-week-old IGF-I KO and control mice. The abun-
dance of MBP and PLP is expressed as percentage of that in control mice.
A line is drawn at 100% to facilitate comparison. Values represent
mean  SE of three to five samples. *p  0.05; **p  0.01; ***p  0.001
compared with controls.
Figure 5. MBP and PLP mRNA abundance in the cerebral cortex,
brainstem, and diencephalon of 3-week-old IGF-I KO mice and littermate
controls. A, Representative Northern blot hybridization analysis of MBP
and PLP mRNA abundance in 3-week-old IGF-I KO and control mice.
Each lane was loaded with 20 g of total RNA. The IGF-I KO mouse is
indicated by KO. The bottom row shows methylene blue (MB) staining of
the 18 S rRNA bands. B, Quantitative analysis of MBP and PLP mRNA
abundance in 3-week-old IGF-I KO mice and control mice. The abun-
dance of MBP and PLP mRNA is expressed as percentage of control
mice. A line is drawn at 100% to facilitate comparison. Values represent
mean  SE of three to five samples. *p  0.05; **p  0.01 compared with
controls.
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Recombinant human IGF-II migrated identically to the 7.5 kDa
band. Recombinant IGF-I was not recognized by the IGF-II
antibody when similar amounts were applied to the gel. When the
antibody was preincubated with recombinant IGF-II, neither the
7.5 kDa band nor the 12 kDa doublet band was observed (Fig.
9A). These data confirm that the antibody is specific for IGF-II
and likely recognizes both the mature (7.5 kDa) and precursor
forms (12 kDa), with no or very little cross-reactivity with IGF-I.
We then determined and compared IGF-II protein abundance in
the brains of IGF-I KO mice and their controls. When the
quantity of each IGF-II band was combined, the abundance of
IGF-II was increased in the CTX of IGF-I KO mice (Fig. 9B). In
control mice, IGF-II abundance gradually decreased with age,
being 61% of its level in 1-week-old mice at 2 weeks of age and
44% at 10 weeks of age. IGF-II abundance in IGF-I KO mice
was relatively constant through the period studied. In 1-week-old
IGF-I KO mice, IGF-II abundance was 50% greater than in
littermate control mice, and its relative abundance increased to
190% of controls at 2 weeks of age ( p  0.05 compared with its
level in 1-week-old IGF-I KO mice), 182% at 3 weeks of age,
and 160% at 10 weeks of age. The abundance of IGFIR, as well
as that of IRS-1, IRS-2, and IRS-4, was similar in IGF-I KO mice
and littermate controls (Fig. 9C,D).
DISSCUSION
Our data show that myelin staining, expression of myelin-specific
protein genes, and oligodendrocyte number are significantly re-
duced in IGF-I KO mice during the first 3 weeks of postnatal life.
This finding is consistent with our previous reports that myelina-
tion is decreased in the brain of Tg mice that ectopically express
IGFBP-1, an inhibitor of IGF action, although it is increased
when IGF-I is overexpressed in brain (Ye et al., 1995a,b). The
myelin content, expression of myelin-specific proteins, and oligo-
Figure 6. MBP and PLP expression in developing IGF-I KO mice and
their littermate controls. A, Representative Western blots of MBP and
PLP protein abundance in CTX and BS of IGF-I KO and control mice
during development. After detection with anti-MBP and anti-PLP anti-
bodies, the blot was stripped and incubated with anti-actin antibody.
IGF-I KO mouse is indicated by KO. The age of each mouse in weeks ( w)
is indicated at the top. B, Quantitative analysis of MBP and PLP protein
abundance in CTX and BS of IGF-I KO and control mice during devel-
opment. The abundance of MBP and PLP is expressed as percentage of
littermate control mice. C, Quantitative analysis of MBP mRNA abun-
dance in CTX, BS, and DIE in IGF-I KO and control mice during
development. MBP mRNA abundance is expressed as percentage of con-
trol mice. Detection of MBP mRNA in DIE from 10-week-old mice was
not done. A line is drawn at 100% in B and C to facilitate comparison.
Values represent mean  SE from three to five samples. *p  0.05; **p 
0.01; ***p  0.001 compared with littermate controls.
Figure 7. Number of oligodendrocytes and their precursors in the CTX,
CC, and BS of developing IGF-I KO mice and their littermate controls.
The numbers of NG2-positive precursor and GST--positive oligoden-
drocytes is expressed in percentage of total cells. Values represent
mean  SE from three samples. *p  0.05; **p  0.01; ***p  0.001
compared with littermate controls.
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dendrocyte number in IGF-I KO mice, however, increases after
the weanling period, resulting in a normal concentration in adult
IGF-I KO mice. These data demonstrate, therefore, that myeli-
nation is developmentally altered in IGF-I KO mice. Our finding
that IGF-II abundance is increased in the brains of IGF-I KO
mice suggests that IGF-II may partially compensate for the loss of
IGF-I expression and function.
These findings are consistent with those of Beck et al. (1995)
who showed that myelinated axons and myelin sheath thickness
are significantly reduced in adult IGF-I KO mice. The data
reported by Cheng et al. (1998) also are consistent with our
findings, although they reached different conclusions. Studying
whole brains from young adult IGF-I KO mice, they found a 25%
reduction in myelin-associated galactocerebroside and sulfatide
but a similar concentration of several myelin-specific proteins.
They also reported that the number of oligodendrocytes in the
CB and anterior commissure of IGF-I KO mice approximately
correlated with the number of projection neurons. For these
reasons and because they did not study parameters of myelination
before adulthood, they concluded that neuronal factors govern
myelination and that IGF-I does not have a major role in myeli-
nation during development. Although we found that the myelin in
adult IGF-I KO mice was similar to that in normal control mice,
our data clearly demonstrate significant decreases in myelin stain-
ing, the expression of MBP and PLP proteins and their mRNAs,
and the number of oligodendrocytes and their precursors before
adulthood. These data indicate that IGF-I has a significant role in
stimulating proliferation and maturation of oligodendrocytes and
promoting myelin protein expression during development, albeit
it can be subserved by IGF-II and/or other agents, when IGF-I
expression is deficient (see below).
IGF-II, an IGF-I homolog, also interacts with the IGFIR.
Because IGF-II is highly expressed in craniofacial mesenchymal
structures (Rotwein et al., 1988; Hepler and Lund, 1990; Rot-
wein, 1991), the brain is exposed to high IGF-II levels during
prenatal and early postnatal life. In rodents, IGF-II expression
persists in the choroid plexus, leptomeninges, and parenchymal
microvasculature through adulthood (Rotwein et al., 1988; Rot-
wein, 1991; Cavallaro et al., 1993; Logan et al., 1994). Recently,
Logan et al. (Logan et al., 1994; Walter et al., 1999) reported that,
in the brain of adult rats, IGF-II and IGFBP-2 immunoreactivity
colocalizes to the membrane of cells with oligodendrocyte char-
acteristics and to myelin sheaths. Together with the data reviewed
above showing that IGF-II is expressed in the choroid plexus,
leptomeninges, and parenchymal microvasculature in adult ani-
mals, their study suggests that IGF-II is transported to myelin
tracks from its sites of synthesis. Although the precise function of
IGF-II in postnatal rodent brains is not clear, its pattern of
association with oligodendrocytes and myelin suggests that it may
play a role in promoting and/or maintaining myelination (Logan
et al., 1994; Walter et al., 1999). The latter speculation is sup-
ported by the data that IGF-II promotes development and sur-
vival of oligodendrocytes and their precursors in culture (Mc-
Morris et al., 1990; Masters et al., 1991; Barres et al., 1992).
Using Western immunoblot analysis, we found that IGF-II
expression is increased in IGF-I KO mice. We observed increases
in IGF-II-immunoreactive bands at 7.5 and 12 kDa in CTX
and BS. The 7.5 kDa comigrates with recombinant IGF-II and
represents mature IGF-II, whereas the more abundant bands
migrating at 12 kDa likely represent precursor forms. Precursor
IGF-II forms of 10–18 kDa have been reported in multiple tumor
cells lines (Schmitt et al., 1997; Bae et al., 1998) and in the serum
of normal and tumor patients (Hoeflich et al., 1995; Bae et al.,
1998; Christofilis et al., 1998). The expression of IGF-II in de-
veloping and adult rodent CNS has been well studied using a
variety of methods, including immunohistochemistry (Logan et
al., 1994; Walter et al., 1999), in situ hybridization (Cavallaro et
Figure 8. NF and GFAP abundance in developing IGF-I KO and their
littermate controls. A, Representative Western immunoblot of M-NF
protein and GFAP abundance in CTX of IGF-I KO and control mice
during development. IGF-I KO mouse is indicated by KO. The age of
each mouse in weeks (w) is indicated at the top. B, Quantitative analysis
of NF protein abundance in CTX and BS of IGF-I KO and control mice
during development. The abundance of M-NF is expressed as percentage
of control mice. C, Correlation of the abundance of M-NF and of MBP
and PLP protein in CTX and BS of IGF-I KO and control mice. NF data
are superimposed on the data for MBP and PLP protein abundance
shown in Figure 6B. M-NF, MBP, and PLP abundance is expressed as
percentage of that in control mice. A line is drawn at 100% in B and C to
facilitate comparison. Values represent mean  SE from three to five
samples. ˆp  0.06; *p  0.05; **p  0.01; ***p  0.001 compared with
controls.
6048 J. Neurosci., July 15, 2002, 22(14):6041–6051 Ye et al. • IGF-I Deficiency Delays Myelination
al., 1993; Logan et al., 1994; Walter et al., 1999), and RNA
protection assay (Rotwein et al., 1988); however, only a few
studies have documented its molecular forms in brain (Hasel-
bacher et al., 1985). Although the physiologic significance of the
expressed IGF-II precursor is not clear, the precursor derived
from tumors has been shown to have biologic activity, including
promotion of angiogenesis and hexosaminidase secretion (Hoe-
flich et al., 1995; Bae et al., 1998; Christofilis et al., 1998). We
speculate that the increase in IGF-II during rapid myelination
(2–4 weeks of age) and in early adulthood is responsible for the
recovery of myelin-specific protein expression in adult IGF-I KO
mice. Other studies of mouse CNS myelination support this
conclusion. Transgenic mice expressing high levels of IGFBP-1 in
brain exhibit a marked decrease in myelination throughout life
(Ye et al., 1995a,b; Ni et al., 1997). IGFBP-1 has a similar affinity
for both IGF-I and IGF-II (Bach et al., 1993; Oh et al., 1993) and
inhibits the actions of both IGF-I and IGF-II. Thus, when the
actions of both IGFs are inhibited, myelination is decreased in the
adult brain. These data argue that an IGF, either IGF-I or IGF-II,
is necessary for normal myelination. Our data, however, do not
exclude the possibility that other factors, alone or in concert, may
also compensate for the IGF-I loss. In culture, FGF and PDGF,
alone or synergistically with IGF-I, are capable of promoting
oligodendrocyte proliferation and survival (Barres et al., 1992,
1993; Jiang et al., 2001).
Myelination is closely associated with axon growth, and, there-
fore, we sought to assess whether there is a correlation between
deficient axon growth and delayed myelination in IGF-I KO mice.
To provide an index of axon growth during development, we
measured the expression of NF. NF, a class IV intermediate
filament, is composed of three subunits with molecular masses of
200 kDa (high), 150 kDa (medium), and 68 kDa (low). The
expression of each of the three NF subunits increases during
development, and their abundance correlates with the axon
growth (Friede and Samorajski, 1970; Lasek et al., 1983; Hoffman
et al., 1985, 1987). In addition, loss of NF protein results in failure
of axon growth (Zhu et al., 1997; Elder et al., 1998). We found
that, whereas the expression of M-NF and H-NF proteins have a
similar developmental profile in both IGF-I KO and control mice,
the expression of M-NF and H-NF in IGF-I KO mice is signifi-
cantly reduced throughout the brain during development and
remains decreased in adult IGF-I KO mice, suggesting a de-
creased axonal growth and/or axon maturation in adult IGF-I KO
mice. The expression of NF, therefore, does not parallel the
changes in abundance of myelin-specific proteins during develop-
ment in IGF-I KO mice. Although decreased axon growth could
contribute to the alteration in myelination in these mice, axon
influences cannot by themselves explain the pattern of myelina-
tion in IGF-I KO mice.
Beck et al. (1995) and Cheng et al. (1998) also assessed neuron
number in specific regions of IGF-I KO mice. Beck et al. (1995)
reported that the numbers of striatal parvalbumin-positive neu-
Figure 9. IGF-II expression in CTX of IGF-I KO mice. A, Representative Western immunoblot of IGF-II protein abundance in IGF-I KO and control
mice. CTX protein (80 g) from a 2-week-old IGF-I KO mouse and a littermate control, recombination human IGF-II (II; 200 ng), and IGF-I (I; 200
ng) were, respectively, loaded in each lane. IGF-I KO mouse is indicated by KO. The right lane represents protein (80 g) from CTX of a 2-week-old
control mouse reacted with the anti-IGF-II antibody that was preincubated with 5 g/ml IGF-II for 1 hr at room temperature (Pre-II ). B, Quantitative
analysis of IGF-II abundance in the CTX of IGF-I KO and control mice. IGF-II protein abundance is expressed as percentage of control mice. A line
is drawn at 100% to facilitate comparison. Values represent mean  SE from three to four samples. *p  0.05; **p  0.01 compared with controls. C,
Representative Western immunoblots of IGFIR, IRS-1, IRS-2, and IRS-4 in IGF-I KO and control mice. CTX protein (30 g) from a 2-week-old IGF-I
KO mouse and a littermate control were loaded in each lane. IGF-I KO mouse is indicated by KO. D, Quantitative analysis of IGFIR, IRS-1, IRS-2,
and IRS-4 abundance in the CTX of IGF-I KO and control mice. Values represent mean  SE from three to five samples.
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rons and hippocampal granular neurons were significantly re-
duced, whereas the numbers of cortical projection neurons in
CTX layers III and V and dopaminergic neurons do not differ in
IGF-I KO and control mice. Cheng et al. (1998) indicated that
there is significant decrease in olfactory bulb neurons but not in
Purkinje cells in IGF-I KO mice. Together, it seems likely that
IGF-I deficiency reduces overall neuron number but that the
influence of IGF-I differs among brain regions. This conclusion is
consistent with our findings that there are significant increases in
neuron number in some but not all medullary nuclei in IGF-I-
overexpressing transgenic mice (Dentremont et al., 1999).
Taken in aggregate, evidence for an important role for IGF-I in
oligodendrocyte development and in myelination is strong. We
believe that IGF-I is a major component of the signaling mech-
anisms that regulate myelination during normal development.
IGF-II also may have a role in regulating myelination, and it can,
at least in part, serve as an IGF-I surrogate in IGF-I-deficient
states. It is clear, however, that many of signaling mechanisms are
involved in the regulation of myelination.
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